• Return to Headlines

Halozyme Therape Down 2.7% Since SmarTrend Downtrend Call (HALO)

By David Diaz

SmarTrend identified a Downtrend for Halozyme Therape (NASDAQ:HALO) on August 9th, 2019 at $15.93. In approximately 2 months, Halozyme Therape has returned 2.73% as of today's recent price of $15.49.

Halozyme Therape share prices have moved between a 52-week high of $18.27 and a 52-week low of $13.24 and are now trading 17% above that low price at $15.49 per share. Over the past week, the 200-day moving average (MA) has gone up 0.2% while the 50-day MA has declined 0.7%.

Halozyme Therapeutics, Inc. is a biopharmaceutical company developing products for the diabetes, cancer, dermatology, and drug delivery markets. The Company's platform technology is based on recombinant human hyaluronidase plus additional enzymes. Halozyme applies its technology to its proprietary programs and to partnerships with pharmaceutical companies.

SmarTrend will continue to scan these moving averages and a number of other proprietary indicators for any changes in momentum for shares of Halozyme Therape.

Log in and add Halozyme Therape (HALO) to your watchlist today so you can receive a real-time alert when the shares are about to change trend.

Keywords: spotlights halozyme therape

Ticker(s): HALO